Q2 EPS Forecast for Marker Therapeutics Cut by Analyst

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Research analysts at Brookline Capital Markets reduced their Q2 2026 earnings estimates for Marker Therapeutics in a report issued on Friday, May 15th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($0.29) per share for the quarter, down from their previous forecast of ($0.27). The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.18) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.53) EPS, FY2028 earnings at $1.44 EPS, FY2029 earnings at $4.97 EPS and FY2030 earnings at $14.34 EPS.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The company had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.

Marker Therapeutics Price Performance

NASDAQ MRKR opened at $1.39 on Wednesday. The company has a fifty day moving average of $1.44 and a two-hundred day moving average of $1.44. The firm has a market capitalization of $23.17 million, a price-to-earnings ratio of -2.28 and a beta of 1.43. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07.

Institutional Trading of Marker Therapeutics

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Marker Therapeutics during the third quarter valued at $25,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics during the third quarter valued at $33,000. Jane Street Group LLC purchased a new stake in shares of Marker Therapeutics during the second quarter valued at $33,000. Boyer Financial Services Inc. purchased a new stake in shares of Marker Therapeutics during the fourth quarter valued at $57,000. Finally, XTX Topco Ltd boosted its stake in shares of Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after purchasing an additional 36,269 shares during the period. 22.39% of the stock is owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.